# Pulmatrix (PULM) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/PULM
## Company Profile
- Ticker: PULM
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: Respiratory
## Stock Data
- Close: 1.36 USD
- Market cap: 4821016.2 USD
- Last updated: 2026-09-03
## Business Overview
### Inhaled Drug-Delivery Company
Pulmatrix developed inhaled therapies using its proprietary iSPERSE dry-powder technology. The company is seeking partners or other monetization routes for its legacy clinical assets while pursuing a merger with Eos SENOLYTIX.
### iSPERSE Technology
iSPERSE creates small, dense, dispersible particles intended to improve pulmonary drug delivery compared with conventional dry powders.
### PUR1900
PUR1900 is an inhaled formulation of itraconazole for fungal lung disease. Partner Cipla controls continued development in India.
### PUR3100 and PUR1800
PUR3100 is a Phase 2-ready inhaled dihydroergotamine program for acute migraine, while PUR1800 is an inhaled kinase inhibitor previously studied in chronic obstructive pulmonary disease.
## Why The Stock Is Moving

As of Sep 3, 2026, PULM closed down 7.48% at $1.36. No new same-company headline was identified in the current news window.

## Future Catalysts

- Initiation of the Cipla-led Phase 3 study of PUR1900 in India in 2026.

## Recent News
- 2026-08-13 12:15 EST — [Pulmatrix Announces Second Quarter 2026 Financial Results and Progress on Merger](https://biopharmsignal.com/news/PULM/pulmatrix-announces-second-quarter-2026-financial-results-and-progress-on-merger-b9f3cb56) — Source: Pulmatrix
- 2026-05-15 12:20 EST — [Pulmatrix Announces First Quarter 2026 Financial Results](https://biopharmsignal.com/news/PULM/pulmatrix-announces-first-quarter-2026-financial-results) — Source: Pulmatrix
- 2026-04-21 12:00 EST — [Pulmatrix Announces Closing of Preferred Stock Transaction as Part of Planned Merger](https://biopharmsignal.com/news/PULM/pulmatrix-announces-closing-of-preferred-stock-transaction-as-part-of-planned-merger) — Source: Pulmatrix
- 2026-03-26 12:00 EST — [Pulmatrix and Eos SENOLYTIX Announce Merger Agreement to Advance Novel Mitochondrial Therapies to Improve Healthspan](https://biopharmsignal.com/news/PULM/pulmatrix-and-eos-senolytix-announce-merger-agreement-to-advance-novel-mitochondrial-therapies-to-improve-healthspan) — Source: Pulmatrix
- 2026-03-02 13:00 EST — [Pulmatrix Announces Termination of Prior Planned Merger and Continues Pursuit of Alternative Merger Opportunities](https://biopharmsignal.com/news/PULM/pulmatrix-announces-termination-of-prior-planned-merger-and-continues-pursuit-of-alternative-merger-opportunities) — Source: Pulmatrix